Alaunos Therapeutics (NASDAQ:TCRT) Trading 20.6% Higher – Still a Buy?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) shares traded up 20.6% on Wednesday . The company traded as high as $2.88 and last traded at $2.81. 51,176 shares traded hands during trading, an increase of 206% from the average session volume of 16,703 shares. The stock had previously closed at $2.33.

Alaunos Therapeutics Stock Down 8.2 %

The business’s 50 day moving average price is $2.44 and its 200-day moving average price is $4.76.

Institutional Trading of Alaunos Therapeutics

A hedge fund recently bought a new stake in Alaunos Therapeutics stock. Virtu Financial LLC acquired a new stake in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 15,440 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned 0.10% of Alaunos Therapeutics at the end of the most recent quarter. 27.72% of the stock is owned by hedge funds and other institutional investors.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.